Alternative HIV Therapies

We concur with the letter appearing in The Scientist, Feb. 17, 1997, by H. Hugh Fudenberg [page 13], which states that potentially effective alternative HIV therapies exist today and are attracting interest and undergoing active investigation. These alternative therapies have not been given fair consideration in comparison to the exploitation of pharmaceuticals. In the past, the proclamation that AZT would revolutionize the treatment of this life-threatening illness and provide a possible cure

Written byLinda Shecterle
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

We concur with the letter appearing in The Scientist, Feb. 17, 1997, by H. Hugh Fudenberg [page 13], which states that potentially effective alternative HIV therapies exist today and are attracting interest and undergoing active investigation. These alternative therapies have not been given fair consideration in comparison to the exploitation of pharmaceuticals. In the past, the proclamation that AZT would revolutionize the treatment of this life-threatening illness and provide a possible cure has been only partially true. When AZT did not live up to all hopes, other pharmaceuticals were developed and released with equal promise. These have also met with less than expected results, until the new wave of protease inhibitors. The initial data on these protease inhibitors appear promising; however, adverse reactions have limited their universal use. Eventual resistance is an issue that has been considered with marginal acceptance, and because of this its full impact has yet to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies